Emory University

Bristol-myers Squibb Compnay

University of Manitoba

Judith A Kapp

Harish C Joshi

Fuqiang Liu

Yong Ke

Peter S Linsley

Keqiang Ye

Alec Sehon

Collin J Weber

Susan A Safley

Glen M Lang

Cheryl Armstrong

David Archer

Jaren Landen

Ye Keqiang

Mary K Hagler

An adjuvant composition comprising noscapine and its derivatives, for use in the treatment of tumors, cancer, as an adjuvant for vaccines.

Noscapine derivatives as adjuvant compositions and methods of use thereof

This invention provides a method of inhibiting viable cells transplanted into a subject from being destroyed by the subject's immune system which comprises: a) containing the viable cells, or tissue comprising the viable cells, prior to transplantation within a device comprising a semipermeable membrane; and b) treating the subject with a substance which inhibits an immune-system costimulation event in an amount effective to inhibit the subject's immune system from responding to said contained cells or tissue. In one embodiment, the substance which inhibits an immune-system costimulation event is CTLA4. Also provided by this invention is a method of treating diabetes in a subject which comprises: a) containing viable insulin-producing cells, or tissue comprising such cells, within a device comprising a semipermeable membrane; b) transplanting an effective amount of such contained viable insulin-producing cells into the subject; and c) treating the subject with an effective amount of a substance which inhibits an immune-system costimulation event.

Method of inhibiting immune system destruction of transplanted viable cells

Delivery systems and methods for noscapine and noscapine derivatives, useful as anticancer agents

Compounds such as formula (I) are useful in the treatment of tumor cells and the treatment of cancer.

Noscapine and noscapine derivatives, useful as anticancer agents

A method for specifically suppressing the capacity of a mammal receiving gene therapy to mount an immune response to a given expressed gene of the deficient gene in question, which response is caused by the administration of 'foreign' DNA encoding an antigenic protein or vectors comprising such DNA for expression of the deficient gene in the patient receiving gene therapy.

Method for gene therapy involving suppression of an immune response

Growing community of inventors

Atlanta, GA, United States of America

Judith A Kapp